Table 1 Characteristics and baseline of patients
| Â | FAH-SYSU | FAH-NAU | SAH-SYSU | ACH-GZMU | Total |
|---|---|---|---|---|---|
Characteristics | Patients (139) | Patients(90) | Patients (25) | Patients (10) | 264 |
Age | Â | Â | Â | Â | Â |
Mean (SD) | 56.7 (12.9) | 58.0 (11.7) | 59.1 (11.7) | 57.0 (12.0) | 57.3 (12.9) |
Median [Min, Max] | 58.0 [26.0, 88.0] | 58.5 [22.0, 86.0] | 59.0 [22.0, 86.0] | 59.5 [30.0, 70.0] | 58.5 [22.0, 88.0] |
Sex | Â | Â | Â | Â | Â |
Female | 35 (25.2%) | 35 (38.9%) | 24 (39.3%) | 1 (10.0%) | 77 (29.2%) |
Male | 104 (74.8%) | 55 (61.1%) | 37 (60.7%) | 9 (90.0%) | 187 (70.8%) |
Disease region | Â | Â | Â | Â | Â |
Localized | 46 (33.1%) | 3 (3.3%) | 2 (3.3%) | 1 (10.0%) | 56 (21.2%) |
Metastatic | 93 (66.9%) | 87 (96.7%) | 59 (96.7%) | 9 (90.0%) | 208 (78.8%) |
Differentiation | Â | Â | Â | Â | Â |
Moderate | 27 (19.4%) | 32 (35.6%) | 23 (37.7%) | 1 (10.0%) | 64 (24.6%) |
Poor | 112 (80.6%) | 58 (64.4%) | 38 (62.3%) | 9 (90.0%) | 199 (75.4%) |
Primary Site | Â | Â | Â | Â | Â |
Lower | 45 (32.4%) | 34 (37.8%) | 23 (37.7%) | 4 (40.0%) | 92 (34.8%) |
Middle | 52 (37.4%) | 42 (46.7%) | 34 (55.7%) | 3 (30.0%) | 107 (40.5%) |
Upper | 42 (30.2%) | 14 (15.6%) | 4 (6.6%) | 3 (30.0%) | 65 (24.6%) |
Reaction | Â | Â | Â | Â | Â |
Well reaction | Â | Â | Â | Â | 128 (48.4%) |
iCR | 1 (0.8%) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | 1 (0.4%) |
iPR | 67 (48.2%) | 43 (47.8%) | 13 (52%) | 4 (40.0%) | 127 (48.1%) |
Poor reaction | Â | Â | Â | Â | 136 (51.6%) |
iSD | 38 (27.3%) | 29 (32.2%) | 4 (16%) | 5 (50.0%) | 76 (28.8%) |
iPD | 33 (23.7%) | 18 (20.0%) | 8 (32%) | 1 (10.0%) | 60 (22.7%) |
WSIs | 159 (50.8%) | 100 (31.9%) | 44 (14.1%) | 10 (3.2%) | 313 |